107 filings
6-K
NYXH
Nyxoah S.A.
2 Jan 25
Current report (foreign)
4:05pm
6-K
NYXH
Nyxoah S.A.
13 Dec 24
Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England
4:10pm
6-K
NYXH
Nyxoah S.A.
2 Dec 24
Information on the total number of voting rights and shares
4:10pm
6-K
NYXH
Nyxoah S.A.
20 Nov 24
Current report (foreign)
4:21pm
6-K
NYXH
Nyxoah S.A.
18 Nov 24
Current report (foreign)
4:42pm
S-8
0s527r8m 1noe5ad
8 Nov 24
Registration of securities for employees
4:44pm
6-K
au78tcrtdr7 dixjbyh
6 Nov 24
Nyxoah Reports Third Quarter Financial and Operating Results
4:11pm
6-K
wo1ppcsm
5 Nov 24
Nyxoah Appoints John Landry as Chief Financial Officer
4:10pm
6-K
8cv6uh wdxz4
28 Oct 24
Current report (foreign)
4:15pm
6-K
sykn7 30uh
15 Oct 24
Current report (foreign)
4:45pm
6-K
rh79of6 rrwohwc
9 Oct 24
Current report (foreign)
4:37pm
6-K
k179x3 cd3w
7 Oct 24
Nyxoah Raises $27 Million through its At-the-Market Offering
5:24pm
6-K
dhwaq8igkez
27 Sep 24
Current report (foreign)
6:09pm
6-K
h3kqdnnuzoaong5jq
6 Aug 24
Nyxoah Reports Second Quarter and First Half 2024 Financial and Operating Results
4:14pm
6-K
is6uoqtgzhrzntxmu2wm
17 Jul 24
Nyxoah Appoints Scott Holstine as Chief Commercial Officer
4:05pm
6-K
jv2e cft0ze
5 Jul 24
Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank
4:05pm
6-K
1wcn2wijb o95vlqna5
1 Jul 24
Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA
4:10pm
6-K
1dnd2d
28 Jun 24
Information on the total number of voting rights and shares
6:46pm
6-K
qmxsw3i
3 Jun 24
Current report (foreign)
4:24pm
6-K
t3ai 8gypdru23lqswuw
31 May 24
Nyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase Additional Shares
4:05pm